Application Deadline: 30.11.2019
ESPGHAN Trainee Regular (200.00€)
ESPGHAN Member Regular (350.00€)
Non-Member Trainee Regular (300.00€)
Non-Member Regular (450.00€)
Knowledge in the diagnostic and therapeutic management of several liver diseases of has increased in the past decades. However, management of acute liver failure (ALF) in infants and children and investigation of its causes remains perplexing in clinical practice.
The Hepatology Committee of ESPGHAN has decided to organize a three-day Monothematic Conference in order to share the latest expertise on the diagnosis and management of ALF in the pediatric age group.
Specifically, the epidemiology, the clinical presentation of ALF and its causes in all pediatric age groups will be discussed providing clinical tips for suspicion of underlying metabolic liver disease. The role of liver biopsy and molecular testing will be discussed, as well as the criteria for transfer to a tertiary care center. Management of complications such as hepatic encephalopathy, coagulopathy, ascites and renal disease will be discussed in one session. Another session, will concentrate on nutrition support, the role of artificial liver/kidney support devices and the indications of liver transplantation in each setting.
Future research goals, and present clinical dilemmas in the diagnosis and management of ALF, will be discussed, by a panel of experienced hepatologists.
We expect to attract gastroenterologists and hepatologists for pediatric and for adult patients, pediatric and hepatobiliary surgeons, from Europe and around the world and to encourage collaboration and exchange of knowledge.
REGISTRATION (to open September 01 2019)
Registration Deadline: November 30, 2019
Early Bird: November 15, 2019
Late Registration: November 30, 2019
Please use the online regsistration on this page to regsiter for the conference. regsitrations by email cannot be accepted. Should you experience any issues with the registration tool, please contact email@example.com.
Participants will be selected on a first come first serve basis. The number of participants is limited. Kindly be aware that the conference might thus be full before the deadline. Additional registrants will be added to our waiting list. Priority will be given to ESPGHAN Members.
ESPGHAN will arrange and cover the following for registered delegates:
- two nights of accommodation at our contracted hotel (Jan 30 and Jan 31)
- dinners on Jan 30 and Feb 01
- congress material
Aglaia Zellos (Local Organiser)
Henkjan Verkade (Chair ESPGHAN Hepatology Committee)
General rules for abstract submission: to be confirmed
Deadline for submission: 1 December 2019
Thursday, January 30
Session 1. Acute liver failure-Etiology and diagnostic approach
14.00-14.30 Definition of ALF and Epidemiology–where do we stand? (R. Squires; Pittsburgh, US)
14.30-15.00 Acute liver Failure in neonates and infants (D. Debray; Paris, France)
15.00-15.30 Recurrent Acute Liver failure (C. Staufner; Heidelberg, Germany)
15.30-16.00 DILI and toxins (B. Fischler; Stockholm, Sweden)
16.00-16.30 Coffee Break
16.30-17.00 Abstracts/interactive case
17.00-17.30 ALF and immune dysregulation (A. Worth; London, UK)
17.30-18.00 Infections and ALF (G. Indolfi; Florence, Italy)
Friday, January 31
Session 2. Acute liver Failure-Initial Management Dilemmas
09.00 – 09.30 New insights in the treatment of hepatic encephalopathy (S. Clement de Clety; Brussels, Belgium)
09.30-10.00 Coagulopathy in acute Liver Failure (T. Lisman; Groningen, Netherlands)
10.00-10.30 Acute on Chronic Liver Failure and SIRS (M. Samyn; London, UK)
10.30-11.00 Coffee Break
11.30-12.00 The role of imaging in diagnosis and prognosis (G. Gupte; Birmingham, UK)
12.00-12:30 Lessons learned from adults (G. Auzinger; London, UK)
Session 3. Acute liver Failure-Treatment
13.30-14.00 Medical treatment for PALF (N. Hadzic; London, UK)
14.00-14.15 Nutritional support in the ICU (S. Mancell; London, UK)
14.15-15.45 Renal replacement therapy (R. Greda; Poland)
15.15-15.45 Coffee Break
15.45-16.15 Is there a role for Extracorporeal Membrane Oxygenation (ECMO)? (S. Renolleau; Paris, France)
16.15-16.45 Listing criteria for liver transplantation: when to list or unlist? (U. Baumann, Hannover, Germany)
16.45-17.15 ALF treatment: a personal perspective over the years (E. Alonso; Chicago, USA)
Saturday February 01
Session 4. ALF: Further Directions
09.00 – 09.30 Bridging to liver recovery: current trials (A. Dhawan; London, UK)
09.30 – 10.00 Abstract
09.45 – 10.15 HRQoL and neurocognitive outcomes (A. Em; Chicago, USA)
10.15 – 10.45 Coffee Break
11.00 – 11.30 What is the future of ALF? (R. Squires; Pittsburgh, US)
11.30 – 12.00 Summary and closing remarks (A. Zellos; Athens, Greece)